BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  US Device


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Halozyme Therapeutics, Inc. 

11388 Sorrento Valley Road

San Diego  California  92121  U.S.A.
Phone: 858-794-8889 Fax: 858-259-2539


View Clinical Trials from BioPharm Insight

Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at

 Key Statistics

Ownership: Public

Web Site: Halozyme Therapeutics, Inc.
Employees: 152
Symbol: HALO

 Company News
FDA Orders Halozyme Therapeutics, Inc. (HALO) To Halt Pancreatic Cancer Study 4/10/2014 6:15:25 AM    More...
Halozyme Therapeutics, Inc. (HALO) Announces Preclinical Data Presentations At The American Association for Cancer Research Annual Meeting 4/8/2014 8:30:49 AM    More...
Halozyme Therapeutics, Inc. (HALO) Tanks As Enrollment In Phase 2 Pancreatic Cancer Study Is Halted; Stock Down -27.26% At 5:20PM ET (April 4, 2014) 4/4/2014 6:58:26 AM    More...
Halozyme Therapeutics, Inc. (HALO) Announces Appointment Of Oncology Product Team Leader And Other Executive Transitions 4/2/2014 6:42:59 AM    More...
Halozyme Therapeutics, Inc. (HALO) To Present At The Barclays 2014 Global Healthcare Conference 3/5/2014 7:17:33 AM    More...
Halozyme Therapeutics, Inc. (HALO) Reports Fourth Quarter And Year End 2013 Financial Results 2/28/2014 6:26:31 AM    More...
Halozyme Therapeutics, Inc. (HALO) To Present At The Cowen and Company 34th Annual Healthcare Conference 2/26/2014 6:17:47 AM    More...
Halozyme Therapeutics, Inc. (HALO) To Host Fourth Quarter And 2013 Year-End Financial Results Conference Call 2/21/2014 6:25:03 AM    More...
Halozyme Therapeutics, Inc. (HALO) Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares 2/10/2014 2:38:32 PM    More...
Halozyme Therapeutics, Inc. (HALO) Prices Public Offering Of Common Stock 2/5/2014 5:25:01 AM    More...